
Erasca Inc (ERAS) Stock Forecast & Price Target
Erasca Inc (ERAS) Analyst Ratings
Bulls say
Erasca is a clinical-stage precision oncology company with a promising pipeline focused on RAS/MAPK driven cancers. The recent data update for ERAS-0015, a pan-RAS molecular glue, has demonstrated encouraging early stage data and management has reported high enrollment rates for their AURORAS-1 Phase 1 dose escalation. With a potential best-in-class therapy and multi-blockbuster opportunities, Erasca is well-positioned for success in the large RAS-mutant market. However, there are risks to consider, such as regulatory and commercial risks. With these factors in mind, the 3rd person analyst has a positive outlook on Erasca's stock with a projected price target of $18.
Bears say
Erasca is a clinical-stage precision oncology company focused on discovering and developing therapies for patients with RAS/MAPK pathway-driven cancers. Despite the company's growing confidence in their lead drug candidate, ERAS-0015, there are significant risks involved that could hinder the drug's success, such as regulatory and financial risks. Topline data for ERAS-0015 and ERAS-4001, as well as updates on strategic focus and enrollment in expansion cohorts, will be important factors to reassess the company's potential market opportunity in multi-billion dollar indications.
This aggregate rating is based on analysts' research of Erasca Inc and is not a guaranteed prediction by Public.com or investment advice.
Erasca Inc (ERAS) Analyst Forecast & Price Prediction
Start investing in Erasca Inc (ERAS)
Order type
Buy in
Order amount
Est. shares
0 shares